Biotechnology Research This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 20.

Advancement in Infection Control of opportunistic Pathogen (Aspergillus spp.): Adjunctive agents.
Abstract There is continuous emergence of resistant strains which leads to urgent need to discover new antifungal agents. The investigation of adjunctive agents for antifungal activity might help to optimize the therapy for Invasive Aspergillosis (IA). The chelating agents Ethylenediamine Tetraacetic Acid (EDTA) & Disodium salt of EDTA (DiEDTA) as adjunct to antifungal drugs have been investigated against 8 pathogenic isolates of Aspergillus spp. The MIC (Minimum Inhibitory Concentration) found by DDA (Disc Diffusion Assay) is 7.50-15.0 µg/disc; by MDA (Microbroth Dilution Assay) is 30.0-49.13 µg/ml & SGI...
Source: Current Pharmaceutical Biotechnology - January 9, 2013 Category: Biotechnology Authors: Ruhil S, Balhara M, Dhankhar S, Kumar M, Kumar V, Chhillar AK Tags: Curr Pharm Biotechnol Source Type: research

Physical and structural stability of the monoclonal antibody, trastuzumab (Herceptin®), intravenous solutions.
In this study, the stability of trastuzumab (Herceptin®) intravenous (i.v.) solutions, an IgG1 monoclonal antibody (mAb), indicated for the treatment of HER2 positive breast cancer, stored under refrigerated conditions, was evaluated over 28 days. No change in visual appearance or average particle size was observed. The pH values of the trastuzumab i.v. solutions remained stable over time. Interestingly, no change in trastuzumab monomer concentration was observed throughout the 28-day study, as determined by SEC-HPLC. SDS-PAGE showed only a monomer band corresponding to the molecular weight of trastuzumab. Circular dichro...
Source: Current Pharmaceutical Biotechnology - January 9, 2013 Category: Biotechnology Authors: Pabari RM, Ryan B, Ahmad W, Ramtoola Z Tags: Curr Pharm Biotechnol Source Type: research

Recombinant Salmonella Vaccination Technology and Its Application to Human Bacterial Pathogens.
Abstract Salmonella enterica is a Gram-negative intracellular bacterial pathogen which causes salmonellosis in humans and animals. During the past several decades, extensive studies have shown that the attenuated Salmonella vaccine vector is an optimal vehicle for delivering passenger antigens to mucosal sites to induce humoral, cellular, and mucosal immunity. This immunity leads to protection against challenges with the wild-type pathogens from which the passenger antigens were derived. A myriad of studies have demonstrated that using attenuated Salmonella vaccines for recombinant multivalent vaccine construction ...
Source: Current Pharmaceutical Biotechnology - January 9, 2013 Category: Biotechnology Authors: Zhang S, Walters N, Cao L, Robison A, Yang X Tags: Curr Pharm Biotechnol Source Type: research

A family 5 β-mannanase from the thermophilic fungus Thielavia arenaria XZ7 with typical thermophilic enzyme features.
Abstract A novel β-mannanase gene, man5XZ7, was cloned from thermophilic fungus Thielavia arenaria XZ7, and successfully expressed in Pichia pastoris. The gene (1,110 bp) encodes a 369-amino acid polypeptide with a molecular mass of approximately 40.8 kDa. The deduced sequence of Man5XZ7 consists of a putative 17-residue signal peptide and a catalytic module belonging to glycoside hydrolase (GH) family 5, and displays 76 % identity with the experimentally verified GH 5 endo-β-1,4-mannanase from Podospora anserina. Recombinant Man5XZ7 was optimally active at 75 °C and pH 5.0 and exhibited high activity at a...
Source: Applied Microbiology and Biotechnology - January 9, 2013 Category: Microbiology Authors: Lu H, Zhang H, Shi P, Luo H, Wang Y, Yang P, Yao B Tags: Appl Microbiol Biotechnol Source Type: research

The intracellular galactoglycome in Trichoderma reesei during growth on lactose.
Abstract Lactose (1,4-0-β-D-galactopyranosyl-D-glucose) is used as a soluble carbon source for the production of cellulases and hemicellulases for-among other purposes-use in biofuel and biorefinery industries. The mechanism how lactose induces cellulase formation in T. reesei is enigmatic, however. Previous results from our laboratory raised the hypothesis that intermediates from the two galactose catabolic pathway may give rise to the accumulation of intracellular oligogalactosides that could act as inducer. Here we have therefore used high-performance anion-exchange chromatography-mass spectrometry to study the...
Source: Applied Microbiology and Biotechnology - January 9, 2013 Category: Microbiology Authors: Karaffa L, Coulier L, Fekete E, Overkamp KM, Druzhinina IS, Mikus M, Seiboth B, Novák L, Punt PJ, Kubicek CP Tags: Appl Microbiol Biotechnol Source Type: research

Purification and characterization of a new alginate lyase from a marine bacterium Vibrio sp.
Abstract An alginate lyase-producing bacterial strain, Vibrio sp. QY105, was isolated from sea mud of Qingdao. It secreted 90 % of total enzyme activity within the first 20 h of fermentation. An alginate lyase, AlyV5, with an apparent MW of 37 kDa and a specific activity of 2152 U/mg was purified from the culture supernatant. It was most active at 38 °C and pH 7.0 in 20 mM Tris/HCl. The enzyme was stable over a broad pH range (6.0-9.0) and retained ~40 % activity after holding at 90 °C for 10 min. AlyV5 showed activities towards both polyguluronate and polymannuronate, but degraded the former more effici...
Source: Biotechnology Letters - January 9, 2013 Category: Biotechnology Authors: Wang Y, Guo EW, Yu WG, Han F Tags: Biotechnol Lett Source Type: research

Synthesis and Functional Characterization of Antibiofilm Exopolysaccharide Produced by Enterococcus faecium MC13 Isolated from the Gut of Fish.
Abstract The synthesis and functional characterization of an antibiofilm exopolysaccharide (EPS) from a probiotic Enterococcus faecium MC13 were investigated. The temperature of 35 °C, pH of 6.5, and salinity of 1-2 % were found to be optimum for EPS production. The sucrose (30 g l(-1)) and yeast extract (20 g l(-1)) acted as suitable carbon and nitrogen sources, respectively, which strongly influenced EPS production with yield of 11.33 and 11.91 g l(-1). Based on the thin layer chromatography, EPS of E. faecium MC13 was found to be a heteropolysaccharide, composed of galactose and glucose sugar units w...
Source: Applied Biochemistry and Biotechnology - January 9, 2013 Category: Biochemistry Authors: Kanmani P, Suganya K, Kumar RS, Yuvaraj N, Pattukumar V, Paari KA, Arul V Tags: Appl Biochem Biotechnol Source Type: research

Development of Industrial Brewing Yeast with Low Acetaldehyde Production and Improved Flavor Stability.
Abstract Higher acetaldehyde concentration in beer is one of the main concerns of current beer industry in China. Acetaldehyde is always synthesized during beer brewing by the metabolism of yeast. Here, using ethanol as the sole carbon source and 4-methylpyrazole as the selection marker, we constructed a new mutant strain with lower acetaldehyde production and improved ethanol tolerance via traditional mutagenesis strategy. European Brewery Convention tube fermentation tests comparing the fermentation broths of mutant strain and industrial brewing strain showed that the acetaldehyde concentration of mutant strain w...
Source: Applied Biochemistry and Biotechnology - January 9, 2013 Category: Biochemistry Authors: Wang J, Shen N, Yin H, Liu C, Li Y, Li Q Tags: Appl Biochem Biotechnol Source Type: research

Chemical Modification of Ethyl Cellulose-Based Highly Porous Membrane for the Purification of Immunoglobulin G.
Abstract The chemical modification of developed ethyl cellulose-based membrane was carried out to make it suitable for bioseparation. The different reagents were used for the modification of membrane to couple protein A (PA) to study the purification of immunoglobulin G (IgG) from blood. The chemical modification was carried out using relatively simple and mild reaction conditions. The attenuated total reflectance Fourier transform infrared analysis of chemically modified membrane showed new peak at 1,596.06 and 1,716.49 cm(-1). The scanning electron microscopy of PA-coupled membrane, which was used for IgG purifi...
Source: Applied Biochemistry and Biotechnology - January 9, 2013 Category: Biochemistry Authors: Adikane HV, Iyer GJ Tags: Appl Biochem Biotechnol Source Type: research

Effect of Different Variables on the Efficiency of the Baker's Yeast Cell Disruption Process to Obtain Alcohol Dehydrogenase Activity.
Abstract Cell disruption process of dry baker's yeast was studied in this work to obtain maximum activity of alcohol dehydrogenase (ADH). Disruption by ultrasonication, glass beads, and combination of these two methods was compared. A 1.8-fold increase of ADH activity can be achieved by combining glass beads with ultrasonication in comparison to ultrasonication. To achieve maximum volume activity of ADH, the effect of different variables on the cell disruption process was investigated (time, glass bead diameter, mass of glass beads, and ultrasound amplitude). Using the Design-Expert© software, 2(4) factorial exper...
Source: Applied Biochemistry and Biotechnology - January 9, 2013 Category: Biochemistry Authors: Sudar M, Valinger D, Findrik Z, Vasić-Rački D, Kurtanjek Z Tags: Appl Biochem Biotechnol Source Type: research

Dehydration of Ethanol by Facile Synthesized Glucose-Based Silica.
Abstract Bioethanol is considered a potential liquid fuel that can be produced from biomass by fermentation and distillation. Although most of the water is removed by distillation, the purity of ethanol is limited to 95-96 % due to the formation of a low-boiling point, water-ethanol azeotrope. To improve the use of ethanol as a fuel, many methods, such as dehydration, have been proposed to avoid distillation and improve the energy efficiency of extraction. Glucose-based silica, as an adsorbent, was prepared using a simple method, and was proposed for the adsorption of water from water-ethanol mixtures. After adsor...
Source: Applied Biochemistry and Biotechnology - January 9, 2013 Category: Biochemistry Authors: Tang B, Bi W, Row KH Tags: Appl Biochem Biotechnol Source Type: research

People
Nature Biotechnology 31, 84 (2013). doi:10.1038/nbt.2485
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Tags: Careers and Recruitment Source Type: research

Rising compensation for biotech R&D officers
Nature Biotechnology 31, 82 (2013). doi:10.1038/nbt.2474 Author: Michael Francisco
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Michael Francisco Tags: Careers and Recruitment Source Type: research

RESEARCH HIGHLIGHTS
Nature Biotechnology 31, 37 (2013). doi:10.1038/nbt.2479
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Tags: News and Views Source Type: research

Restoration of the gut microbial habitat as a disease therapy
Nature Biotechnology 31, 35 (2013). doi:10.1038/nbt.2475 Author: David A Relman An intestinal infectious disease that is difficult to treat is cured by a defined set of bacterial species.
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: David A Relman Tags: News and Views Source Type: research

Automating the construction of gene ontologies
Nature Biotechnology 31, 34 (2013). doi:10.1038/nbt.2476 Authors: Kara Dolinski & David Botstein Manual curation of biological ontologies is recapitulated by an algorithmic approach, supplementing the Gene Ontology and enabling the discovery of relationships among genes and proteins.
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Kara DolinskiDavid Botstein Tags: News and Views Source Type: research

Double or nothing on cancer immunotherapy
Nature Biotechnology 31, 33 (2013). doi:10.1038/nbt.2471 Authors: Ken-ichi Hanada & Nicholas P Restifo Engineered T cells expressing two receptors distinguish malignant cells from healthy cells even in the absence of a tumor-specific antigen.
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Ken-ichi HanadaNicholas P Restifo Tags: News and Views Source Type: research

Reprogramming paces the heart
Nature Biotechnology 31, 31 (2013). doi:10.1038/nbt.2480 Authors: Edward G Lakatta & Victor A Maltsev Rodent cardiomyocytes are converted into pacemaker cells by viral delivery of a single transcription-factor gene.
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Edward G LakattaVictor A Maltsev Tags: News and Views Source Type: research

Recent patent applications in computational biotechnologies
Nature Biotechnology 31, 30 (2013). doi:10.1038/nbt.2483 Author: Julien Muzard
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Julien Muzard Tags: Feature Source Type: research

The evolving landscape of plant varietal rights in the United States, 1930–2008
Nature Biotechnology 31, 25 (2013). doi:10.1038/nbt.2467 Authors: Philip Pardey, Bonwoo Koo, Jennifer Drew, Jeffrey Horwich & Carol Nottenburg The types of plants being protected, by whom and by what form of varietal right, has changed markedly since the United States first enabled intellectual property protection for plant varieties in 1930.
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Philip PardeyBonwoo KooJennifer DrewJeffrey HorwichCarol Nottenburg Tags: Feature Source Type: research

Knockout mice created by TALEN-mediated gene targeting
Nature Biotechnology 31, 23 (2013). doi:10.1038/nbt.2477 Authors: Young Hoon Sung, In-Jeoung Baek, Duk Hyoung Kim, Jisun Jeon, Jaehoon Lee, Kyunghee Lee, Daewon Jeong, Jin-Soo Kim & Han-Woong Lee
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Young Hoon SungIn-Jeoung BaekDuk Hyoung KimJisun JeonJaehoon LeeKyunghee LeeDaewon JeongJin-Soo KimHan-Woong Lee Tags: Opinion and Comment Source Type: research

Human embryonic stem cells commonly display large mitochondrial DNA deletions
Nature Biotechnology 31, 20 (2013). doi:10.1038/nbt.2473 Authors: Lindsey Van Haute, Claudia Spits, Mieke Geens, Sara Seneca & Karen Sermon
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Lindsey Van HauteClaudia SpitsMieke GeensSara SenecaKaren Sermon Tags: Opinion and Comment Source Type: research

Lack of evidence for existence of noncanonical RNA editing
Nature Biotechnology 31, 19 (2013). doi:10.1038/nbt.2472 Authors: Robert Piskol, Zhiyu Peng, Jun Wang & Jin Billy Li
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Robert PiskolZhiyu PengJun WangJin Billy Li Tags: Opinion and Comment Source Type: research

The International Serious Adverse Events Consortium's data sharing model
Nature Biotechnology 31, 17 (2013). doi:10.1038/nbt.2470 Authors: Jorge L Contreras, Aris Floratos & Arthur L Holden
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Jorge L ContrerasAris FloratosArthur L Holden Tags: Opinion and Comment Source Type: research

The challenge of personal genomics in Germany
Nature Biotechnology 31, 16 (2013). doi:10.1038/nbt.2469 Authors: Effy Vayena & Barbara Prainsack
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Effy VayenaBarbara Prainsack Tags: Opinion and Comment Source Type: research

There and back again
Nature Biotechnology 31, 13 (2013). doi:10.1038/nbt.2466 Author: John Boyle Vacating industry and joining the academic ranks means leaving the world of order for the satisfying chaos of research.
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: John Boyle Tags: Bioentrepreneur Source Type: research

Around the world in a month
Nature Biotechnology 31, 12 (2013). doi:10.1038/nbt0113-12b
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Tags: News Source Type: research

Algal biofuels questioned
Nature Biotechnology 31, 12 (2013). doi:10.1038/nbt0113-12a Author: Emily Waltz
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Emily Waltz Tags: News Source Type: research

Banking iPS cells
Nature Biotechnology 31, 11 (2013). doi:10.1038/nbt0113-11 Author: Nuala Moran
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Nuala Moran Tags: News Source Type: research

Threat to global GM soybean access as patent nears expiry
Nature Biotechnology 31, 10 (2013). doi:10.1038/nbt0113-10c Author: Daniel Grushkin
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Daniel Grushkin Tags: News Source Type: research

Pan-African genomics
Nature Biotechnology 31, 10 (2013). doi:10.1038/nbt0113-10b Author: Linda Nordling
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Linda Nordling Tags: News Source Type: research

Kite and NCI partner on T cells
Nature Biotechnology 31, 10 (2013). doi:10.1038/nbt0113-10a Author: Moheb Costandi
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Moheb Costandi Tags: News Source Type: research

India flouts patent for blockbuster biologic
Nature Biotechnology 31, 9 (2013). doi:10.1038/nbt0113-9 Author: Killugudi Jayaraman
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Killugudi Jayaraman Tags: News Source Type: research

Anthrax drug first antibacterial mAb to win approval
Nature Biotechnology 31, 8 (2013). doi:10.1038/nbt0113-8 Author: Jeffrey L Fox
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Jeffrey L Fox Tags: News Source Type: research

IOM smacks down California Institute of Regenerative Medicine
Nature Biotechnology 31, 7 (2013). doi:10.1038/nbt0113-7 Author: Laura DeFrancesco
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Laura DeFrancesco Tags: News Source Type: research

Cardiac stem cell therapies inch toward clinical litmus test
Nature Biotechnology 31, 5 (2013). doi:10.1038/nbt0113-5 Author: Cormac Sheridan
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Cormac Sheridan Tags: News Source Type: research

MEK inhibitor nears approval
Nature Biotechnology 31, 4 (2013). doi:10.1038/nbt0113-4 Author: Malorye Allison
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Malorye Allison Tags: News Source Type: research

Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market
Nature Biotechnology 31, 3 (2013). doi:10.1038/nbt0113-3 Author: Ken Garber
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Authors: Ken Garber Tags: News Source Type: research

Failure to launch
Nature Biotechnology 31, 1 (2013). doi:10.1038/nbt.2482 A slew of disappointing product launches suggests biotech companies are ill prepared to navigate an increasingly parsimonious reimbursement environment.
Source: Nature Biotechnology - January 9, 2013 Category: Biotechnology Tags: Editorial Source Type: research

One-on-One with Canaan Partners' Wende Hutton on startup Labrys Biologics
It sounds easier in a press release than it is in real life, but Labrys Biologics Inc. scored the biotech equivalent of a three-pointer: startup funding from well-heeled VCs, an experienced CEO and a Phase II-ready drug in a potentially huge market. The company, which still is looking for space, probably in South San Francisco, last week said it nabbed $31 million in Series A funding from VenBio, Canaan Partners, InterWest Partners and Sofinnova Ventures. It also snagged an experimental treatment…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 8, 2013 Category: Pharmaceuticals Authors: Ron Leuty Source Type: research

Supreme Court Ensures Funding of Research Using Human Embryonic Stem Cells
The US Supreme Court today ended an effort to shut down government support of human embryonic stem cell research, refusing to hear a case that challenged the legality of funding for the work by the National Institutes of Health (NIH). [More]
Source: Scientific American - Official RSS Feed - January 8, 2013 Category: Science Tags: More Science,Health,Society & Policy,More Science,Pharmaceuticals,Biotechnology,Biotechnology,Ethics,Biology Source Type: research

Whitney Young to use $100,000 grant to improve care of the chronically ill
Whitney M. Young Jr. Health Services in Albany, New York, will use a $100,000 grant from the New York State Health Foundation to enhance its care of the chronically ill. As a federally-qualified health center, Whitney M. Young provides primary care, dentistry, and behavioral health services to the poor and uninsured. The center, which has locations in Albany and Troy, sees about 22,000 patients annually through about 59,000 visits. David Shippee, CEO of Whitney M. Young, said adult primary care…
Source: bizjournals.com Health Care:Biotechnology headlines - January 8, 2013 Category: Biotechnology Authors: Barbara Pinckney Source Type: research

Ohio biotech investments hits $292M in 2012
Healthcare technology companies in Ohio attracted $292 million last year, according to the BioEnterprise Midwest Healthcare Venture Investment Report. The marked a 65 percent jump from 2011, when $178 million was invested. Ohio -- which had 70 companies receive investments -- posted the most investment of any other Midwestern state. Related: Click for Dayton-area biotech job expansions. By sector, 2012 equity funding in the Midwest was allocated to biopharmaceutical companies ($487 million), medical…
Source: bizjournals.com Health Care:Biotechnology headlines - January 8, 2013 Category: Biotechnology Source Type: research

Large Calif. REIT buying building near WakeMed North
American Healthcare Investors and Griffin Capital Corp., the co-sponsors of Griffin-American Healthcare REIT II, is buying the 77,000 square feet Physician's Office Pavilion at WakeMed North as part of a 14- building acquistion spree across the Southeast. The building is on the campus of WakeMed North Healthplex, with direct access to the facility via covered walkway. WakeMed Health System, one of Triangle's largest not-for-profit health systems, has announced plans to expand the North Raleigh healthplex…
Source: bizjournals.com Health Care:Biotechnology headlines - January 8, 2013 Category: Biotechnology Source Type: research

Jewish Hospital Medical Center East turns 10
Jewish Hospital Medical Center East, a KentuckyOne Health Inc. facility, celebrates the 10th anniversary of its opening this month. As Business First reported, the center, at 3920 Dutchmans Lane, opened with more than 260,000 square feet for outpatient services. It has served more than 700,000 patients in the last decade. And it was the first major Jewish Hospital facility in the East End to provide outpatient and diagnostic procedures. Click here to read an interview with KentuckyOne vice president…
Source: bizjournals.com Health Care:Biotechnology headlines - January 8, 2013 Category: Biotechnology Source Type: research

Cost savings from e-health records elusive
As Triangle hospitals ramp up their spending to put in place electronic health records – $100 million by WakeMed Health & Hospitals alone – as mandated by the national health reform law, a new study says providers aren't adapting fast enough to realize savings. RAND Corp. says its research shows that adoption is not moving fast enough to achieve a hoped-for $81 billion in annual savings, and that changes in the way care is provided need to be made.
Source: bizjournals.com Health Care:Biotechnology headlines - January 8, 2013 Category: Biotechnology Authors: Dale Gibson Source Type: research

Kindred cuts earnings guidance on Medicare changes
Kindred Healthcare Inc. is expecting lower profit in 2013 as a result of cuts in Medicare reimbursements included in the American Taxpayer Relief Act of 2012. As RTTNews.com reported, Louisville-based Kindred expects to report income from continuing operations of $60 million to $70 million, or $1.10 to $1.30 per share. Previously, Kindred (NYSE: KND) called for 2013 earnings per share of $1.20 to $1.40 per share. Revenue of about $5.9 billion still is expected by company officials.
Source: bizjournals.com Health Care:Biotechnology headlines - January 8, 2013 Category: Biotechnology Source Type: research

Scott, Sebelius talk Medicaid, Obamacare
TALLAHASSEE—After emerging from a meeting with U.S. Health and Human Services Secretary Kathleen Sebelius, Gov. Rick Scott said Monday he asked for the federal government to “expedite” approval of Florida’s controversial proposals to shift most Medicaid beneficiaries into managed-care plans. But Scott offered few details about their discussion on another major issue --- how, or if, the state will carry out key parts of the federal Affordable Care Act. Speaking to reporters in Washington,…
Source: bizjournals.com Health Care:Biotechnology headlines - January 8, 2013 Category: Biotechnology Authors: JIM SAUNDERS Source Type: research

Young adults to pay more for health insurance thanks to Obamacare
Here's another reason for young adults to resent old folks: They're going to pay more for health insurance thanks to a health care reform provision that limits how much older people have to pay for coverage. Beginning in 2014, older Americans can't be charged more than three times what young adults pay for health insurance. In 42 states, the current age band ratio is 5 to 1. Insurers charge older Americans more for insurance because they have more health problems — it makes actuarial sense. But…
Source: bizjournals.com Health Care:Biotechnology headlines - January 8, 2013 Category: Biotechnology Authors: Kent Hoover Source Type: research

Endo, Pfizer settle Medicaid fraud claims in Texas
Drug makers Endo Health Solutions and Pfizer are paying $18.17 million each to the state of Texas to settle Medicaid fraud allegations. Neither company is admitting wrongdoing, the Houston Business Journal reports. Texas’ lawsuits claimed the companies misreported the price of various generic drugs and overcharged Medicaid for certain products. Endo (NASDAQ:ENDP) is based in Chadds Ford, Pa.
Source: bizjournals.com Health Care:Biotechnology headlines - January 8, 2013 Category: Biotechnology Source Type: research